Expectations trend
FY2028 · fiscal year ending 2028-06-30 · fmp
Precision Optics Corp Inc/Mass (POCI)
NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-11-04
$4.95+2.27%
Close 2026-11-05 · 1-day change
NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
0.21 → 0.03 EPS · FY ending Jun 30, 2028 · 1 analyst
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
Change in the same fiscal period’s mean EPS estimate from Oct 5, 2026 to Nov 4, 2026: (new ÷ prior − 1). Contributor count changed from 1 to 1; this is not the number of analysts revising. The ±10% axis is a display range.
The EPS and P/E reference is not available for POCI yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Effective capital allocation supporting growth and stability | Capital allocation remains a concern but is being addressed. | Intact | material negative capital allocation events or worsening financial instability | Qualitative condition This condition has no defined numerical measure. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2028 · fiscal year ending 2028-06-30 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 12, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
POCI is a high-risk, early-stage growth business rather than an established compounder, and its multi-year view is intact with a mild favorable signal. Fiscal 2026 results improved, but the company remains loss-making and evidence on its newer customer and product pipeline is limited.
The valuation evidence is mixed: POCI is described as cheap versus peers, while another measure places it at a 44% premium to peers. The expectations-gap measure is negative, but model confidence is low, so the market’s assumptions are uncertain; the priced-in assessment is tagged justified, with no fragility flags.
Near-term, revenue growth may pause: fiscal 2027 guidance is $30 million to $33 million after fiscal 2026 revenue of $31.5 million, partly due to a satellite-customer pause. Fourth-quarter gross margin improved to 25.3% from 13.0%, and the operating loss narrowed, but full-year gross margin slipped to 17.2% from 17.8%, and the company remains loss-making. A next-call guidance cut and weaker employment data are risks, while recent results and an earnings beat support the current improvement.
The multi-year thesis hinges on whether management can grow customer programs, turn the initial engineering order from a second satellite customer into delivered work, and sustain better margins. Continued strength from healthcare-sector peers could support the sector backdrop, while further employment weakness or a guidance cut would challenge the near-term outlook.
Over the next one to three years, POCI’s improving revenue and quarterly margins support an intact thesis, but ongoing losses, uneven full-year margin progress, and execution risks leave the outcome uncertain. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| Gross profit improved from $0.95M to $2.06M, showing better margins. |
| Improving |
| gross profit falls below $0.95M in any quarter through 2026-Q3 |
Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Revenue growth to at least $8.7M in Q3 2026 | A primary condition in Precision Optics Corp Inc/Mass's published investment case. The stated target is >= $8.7M revenue in 2026-Q3. | Recovered | quarterly revenue falls below $6.7M in any quarter through 2026-Q3 | Revenue: $8.774M FY2026-Q4; GAAP. Published target: >= $8.7M revenue in 2026-Q3. The stored target says 2026-Q3; this source reports FY2026-Q4. Fiscal/calendar alignment needs review. Sep 28, 20268,774,474 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$0.21 → $0.03 · observed estimates
$0.04B → $0.04B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $0.21 | $39,200,000 | 1 / 1 |
| 2026-07-25 | $0.21 | $39,200,000 | 1 / 1 |
| 2026-07-26 | $0.21 | $39,200,000 | 1 / 1 |
| 2026-07-27 | $0.21 | $39,200,000 | 1 / 1 |
| 2026-07-28 | $0.21 | $39,200,000 | 1 / 1 |
| 2026-07-29 | $0.21 | $39,200,000 | 1 / 1 |
| 2026-07-30 | $0.21 | $39,200,000 | 1 / 1 |
| 2026-07-31 | $0.21 | $39,200,000 | 1 / 1 |
| 2026-08-01 | $0.21 | $39,200,000 | 1 / 1 |
| 2026-08-02 | $0.21 | $39,200,000 | 1 / 1 |
| 2026-08-03 | $0.21 | $39,200,000 | 1 / 1 |
| 2026-08-04 | $0.21 | $39,200,000 | 1 / 1 |
| 2026-08-05 | $0.21 | $39,200,000 | 1 / 1 |
| 2026-08-06 | $0.21 | $39,200,000 | 1 / 1 |
| 2026-08-07 | $0.21 | $39,200,000 | 1 / 1 |
| 2026-08-08 | $0.21 | $39,200,000 | 1 / 1 |
| 2026-08-09 | $0.21 | $39,200,000 | 1 / 1 |
| 2026-08-10 | $0.21 | $39,200,000 | 1 / 1 |
| 2026-08-12 | $0.21 | $39,200,000 | 1 / 1 |
| 2026-08-13 | $0.21 | $39,200,000 | 1 / 1 |
| 2026-08-14 | $0.21 | $39,200,000 | 1 / 1 |
| 2026-08-15 | $0.21 | $39,200,000 | 1 / 1 |
| 2026-08-16 | $0.21 | $39,200,000 | 1 / 1 |
| 2026-08-17 | $0.21 | $39,200,000 | 1 / 1 |
| 2026-08-18 | $0.21 | $39,200,000 | 1 / 1 |
| 2026-08-19 | $0.21 | $39,200,000 | 1 / 1 |
| 2026-08-20 | $0.21 | $39,200,000 | 1 / 1 |
| 2026-08-21 | $0.21 | $39,200,000 | 1 / 1 |
| 2026-08-22 | $0.21 | $39,200,000 | 1 / 1 |
| 2026-08-23 | $0.21 | $39,200,000 | 1 / 1 |
| 2026-08-24 | $0.21 | $39,200,000 | 1 / 1 |
| 2026-08-25 | $0.21 | $39,200,000 | 1 / 1 |
| 2026-08-26 | $0.21 | $39,200,000 | 1 / 1 |
| 2026-08-27 | $0.21 | $39,200,000 | 1 / 1 |
| 2026-08-28 | $0.21 | $39,200,000 | 1 / 1 |
| 2026-08-29 | $0.21 | $39,200,000 | 1 / 1 |
| 2026-08-30 | $0.21 | $39,200,000 | 1 / 1 |
| 2026-08-31 | $0.21 | $39,200,000 | 1 / 1 |
| 2026-09-01 | $0.21 | $39,200,000 | 1 / 1 |
| 2026-09-02 | $0.21 | $39,200,000 | 1 / 1 |
| 2026-09-03 | $0.21 | $39,200,000 | 1 / 1 |
| 2026-09-04 | $0.21 | $39,200,000 | 1 / 1 |
| 2026-09-05 | $0.21 | $39,200,000 | 1 / 1 |
| 2026-09-06 | $0.21 | $39,200,000 | 1 / 1 |
| 2026-09-07 | $0.21 | $39,200,000 | 1 / 1 |
| 2026-09-08 | $0.21 | $39,200,000 | 1 / 1 |
| 2026-09-09 | $0.21 | $39,200,000 | 1 / 1 |
| 2026-09-10 | $0.21 | $39,200,000 | 1 / 1 |
| 2026-09-11 | $0.21 | $39,200,000 | 1 / 1 |
| 2026-09-12 | $0.21 | $39,200,000 | 1 / 1 |
| 2026-09-13 | $0.21 | $39,200,000 | 1 / 1 |
| 2026-09-14 | $0.21 | $39,200,000 | 1 / 1 |
| 2026-09-15 | $0.21 | $39,200,000 | 1 / 1 |
| 2026-09-16 | $0.21 | $39,200,000 | 1 / 1 |
| 2026-09-17 | $0.21 | $39,200,000 | 1 / 1 |
| 2026-09-18 | $0.21 | $39,200,000 | 1 / 1 |
| 2026-09-19 | $0.21 | $39,200,000 | 1 / 1 |
| 2026-09-20 | $0.21 | $39,200,000 | 1 / 1 |
| 2026-09-21 | $0.21 | $39,200,000 | 1 / 1 |
| 2026-09-22 | $0.21 | $39,200,000 | 1 / 1 |
| 2026-09-23 | $0.21 | $39,200,000 | 1 / 1 |
| 2026-09-24 | $0.21 | $39,200,000 | 1 / 1 |
| 2026-09-25 | $0.21 | $39,200,000 | 1 / 1 |
| 2026-09-26 | $0.21 | $39,200,000 | 1 / 1 |
| 2026-09-27 | $0.21 | $39,200,000 | 1 / 1 |
| 2026-09-28 | $0.21 | $39,200,000 | 1 / 1 |
| 2026-09-29 | $0.21 | $39,200,000 | 1 / 1 |
| 2026-09-30 | $0.21 | $39,200,000 | 1 / 1 |
| 2026-10-01 | $0.21 | $39,200,000 | 1 / 1 |
| 2026-10-02 | $0.21 | $39,200,000 | 1 / 1 |
| 2026-10-03 | $0.21 | $39,200,000 | 1 / 1 |
| 2026-10-04 | $0.21 | $39,200,000 | 1 / 1 |
| 2026-10-05 | $0.21 | $39,200,000 | 1 / 1 |
| 2026-10-06 | $0.21 | $39,200,000 | 1 / 1 |
| 2026-10-07 | $0.03 | $35,700,000 | 1 / 1 |
| 2026-10-08 | $0.03 | $35,700,000 | 1 / 1 |
| 2026-10-09 | $0.03 | $35,700,000 | 1 / 1 |
| 2026-10-10 | $0.03 | $35,700,000 | 1 / 1 |
| 2026-10-11 | $0.03 | $35,700,000 | 1 / 1 |
| 2026-10-12 | $0.03 | $35,700,000 | 1 / 1 |
| 2026-10-13 | $0.03 | $35,700,000 | 1 / 1 |
| 2026-10-14 | $0.03 | $35,700,000 | 1 / 1 |
| 2026-10-15 | $0.03 | $35,700,000 | 1 / 1 |
| 2026-10-16 | $0.03 | $35,700,000 | 1 / 1 |
| 2026-10-17 | $0.03 | $35,700,000 | 1 / 1 |
| 2026-10-18 | $0.03 | $35,700,000 | 1 / 1 |
| 2026-10-19 | $0.03 | $35,700,000 | 1 / 1 |
| 2026-10-20 | $0.03 | $35,700,000 | 1 / 1 |
| 2026-10-21 | $0.03 | $35,700,000 | 1 / 1 |
| 2026-10-22 | $0.03 | $35,700,000 | 1 / 1 |
| 2026-10-23 | $0.03 | $35,700,000 | 1 / 1 |
| 2026-10-24 | $0.03 | $35,700,000 | 1 / 1 |
| 2026-10-25 | $0.03 | $35,700,000 | 1 / 1 |
| 2026-10-26 | $0.03 | $35,700,000 | 1 / 1 |
| 2026-10-27 | $0.03 | $35,700,000 | 1 / 1 |
| 2026-10-28 | $0.03 | $35,700,000 | 1 / 1 |
| 2026-10-29 | $0.03 | $35,700,000 | 1 / 1 |
| 2026-10-30 | $0.03 | $35,700,000 | 1 / 1 |
| 2026-10-31 | $0.03 | $35,700,000 | 1 / 1 |
| 2026-11-01 | $0.03 | $35,700,000 | 1 / 1 |
| 2026-11-02 | $0.03 | $35,700,000 | 1 / 1 |
| 2026-11-03 | $0.03 | $35,700,000 | 1 / 1 |
| 2026-11-04 | $0.03 | $35,700,000 | 1 / 1 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 1 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.